PMID- 28302531
OWN - NLM
STAT- MEDLINE
DCOM- 20170914
LR  - 20180628
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 396
DP  - 2017 Jun 28
TI  - Resistin potentiates chemoresistance and stemness of breast cancer cells:
      Implications for racially disparate therapeutic outcomes.
PG  - 21-29
LID - S0304-3835(17)30174-X [pii]
LID - 10.1016/j.canlet.2017.03.010 [doi]
AB  - Breast cancer (BC) continues to be the most frequently diagnosed cancer in
      American women, which disproportionately affects women of African-American (AA)
      descent. Previously, we reported greater serum levels of resistin in AA BC
      patients relative to Caucasian-American (CA) patients, and established its role
      in growth and aggressiveness of breast tumor cells. Here we have investigated the
      role of resistin in BC-chemoresistance. MDA-MB-231 and MDA-MB-468 BC cells of CA 
      and AA origin, respectively, were incubated with resistin prior to doxorubicin
      treatment. Our data suggest that resistin conferred chemoresistance to both BC
      cell lines; however, the effect on AA cells was more profound. Furthermore, the
      resistin-induced doxorubicin-resistance was shown to occur due to suppression of 
      apoptosis. Resistin treatment also affected the stemness of BC cells, as
      suggested by reduced cell surface expression of CD24, induced expression of CD44 
      and ALDH1, and increased capability of cells to form mammospheres. Mechanistic
      studies revealed that resistin-induced chemoresistance, apoptosis and stemness of
      BC cells were mediated through STAT3 activation. Taken together, our findings
      provide novel insight into the role of resistin in BC biology, and strengthen its
      role in racially disparate clinical outcomes.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Deshmukh, Sachin K
AU  - Deshmukh SK
AD  - Department of Oncologic Sciences, Mitchell Cancer Institute, University of South 
      Alabama, Mobile, AL, USA.
FAU - Srivastava, Sanjeev K
AU  - Srivastava SK
AD  - Department of Oncologic Sciences, Mitchell Cancer Institute, University of South 
      Alabama, Mobile, AL, USA.
FAU - Zubair, Haseeb
AU  - Zubair H
AD  - Department of Oncologic Sciences, Mitchell Cancer Institute, University of South 
      Alabama, Mobile, AL, USA.
FAU - Bhardwaj, Arun
AU  - Bhardwaj A
AD  - Department of Oncologic Sciences, Mitchell Cancer Institute, University of South 
      Alabama, Mobile, AL, USA.
FAU - Tyagi, Nikhil
AU  - Tyagi N
AD  - Department of Oncologic Sciences, Mitchell Cancer Institute, University of South 
      Alabama, Mobile, AL, USA.
FAU - Al-Ghadhban, Ahmed
AU  - Al-Ghadhban A
AD  - Department of Oncologic Sciences, Mitchell Cancer Institute, University of South 
      Alabama, Mobile, AL, USA.
FAU - Singh, Ajay P
AU  - Singh AP
AD  - Department of Oncologic Sciences, Mitchell Cancer Institute, University of South 
      Alabama, Mobile, AL, USA; Department of Biochemistry and Molecular Biology,
      College of Medicine, University of South Alabama, Mobile, AL, USA.
FAU - Dyess, Donna L
AU  - Dyess DL
AD  - Department of Oncologic Sciences, Mitchell Cancer Institute, University of South 
      Alabama, Mobile, AL, USA.
FAU - Carter, James E
AU  - Carter JE
AD  - Department of Pathology, College of Medicine, University of South Alabama,
      Mobile, AL, USA.
FAU - Singh, Seema
AU  - Singh S
AD  - Department of Oncologic Sciences, Mitchell Cancer Institute, University of South 
      Alabama, Mobile, AL, USA; Department of Biochemistry and Molecular Biology,
      College of Medicine, University of South Alabama, Mobile, AL, USA. Electronic
      address: seemasingh@health.southalabama.edu.
LA  - eng
GR  - R01 CA204801/CA/NCI NIH HHS/United States
GR  - U01 CA185490/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20170314
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Resistin)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Antibiotics, Antineoplastic/pharmacology
MH  - Apoptosis/drug effects
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Doxorubicin/*pharmacology
MH  - Drug Interactions
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - *Health Status Disparities
MH  - Humans
MH  - Neoplastic Stem Cells/drug effects/metabolism/pathology
MH  - Resistin/metabolism/*pharmacology
MH  - Treatment Outcome
PMC - PMC5437742
MID - NIHMS862446
OTO - NOTNLM
OT  - *Breast cancer
OT  - *Chemoresistance
OT  - *Racial disparity
OT  - *Resistin
OT  - *STAT3
OT  - *Stemness
EDAT- 2017/03/18 06:00
MHDA- 2017/09/15 06:00
CRDT- 2017/03/18 06:00
PHST- 2017/02/14 00:00 [received]
PHST- 2017/03/04 00:00 [revised]
PHST- 2017/03/07 00:00 [accepted]
PHST- 2017/03/18 06:00 [pubmed]
PHST- 2017/09/15 06:00 [medline]
PHST- 2017/03/18 06:00 [entrez]
AID - S0304-3835(17)30174-X [pii]
AID - 10.1016/j.canlet.2017.03.010 [doi]
PST - ppublish
SO  - Cancer Lett. 2017 Jun 28;396:21-29. doi: 10.1016/j.canlet.2017.03.010. Epub 2017 
      Mar 14.